It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL).
Should read:
It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL).
Page 1701, section 1, paragraph 2, lines 5-9: The following sentence, which previously read:
The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL) who have received at least two other prior therapies [3, 4] .
The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL) who have received at least two other prior therapies [3, 4] .
